Lindman H - Search Results

1

A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden.

Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, Tennvall-Nittby L, Pettersson-Sköld D, Sverrisdottir A, Söderberg M, Klaar S, Bergh J. Andersson J, et al. Among authors: lindman h. Acta Oncol. 2002;41(3):276-81. doi: 10.1080/02841860260088827. Acta Oncol. 2002. PMID: 12195747

2

Noninvasive detection of any-stage cancer using free glycosaminoglycans.

Bratulic S, Limeta A, Dabestani S, Birgisson H, Enblad G, Stålberg K, Hesselager G, Häggman M, Höglund M, Simonson OE, Stålberg P, Lindman H, Bång-Rudenstam A, Ekstrand M, Kumar G, Cavarretta I, Alfano M, Pellegrino F, Mandel-Clausen T, Salanti A, Maccari F, Galeotti F, Volpi N, Daugaard M, Belting M, Lundstam S, Stierner U, Nyman J, Bergman B, Edqvist PH, Levin M, Salonia A, Kjölhede H, Jonasch E, Nielsen J, Gatto F. Bratulic S, et al. Among authors: lindman h. Proc Natl Acad Sci U S A. 2022 Dec 13;119(50):e2115328119. doi: 10.1073/pnas.2115328119. Epub 2022 Dec 5. Proc Natl Acad Sci U S A. 2022. PMID: 36469776 Free PMC article.

3

Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.

Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, Lindman H, Leon-Ferre RA, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Perez EA, Thompson EA. Carter JM, et al. Among authors: lindman h. Nat Commun. 2023 Apr 18;14(1):2215. doi: 10.1038/s41467-023-37806-0. Nat Commun. 2023. PMID: 37072398 Free PMC article.

4

Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein.

Lindman H, Taube A, Bergh JC. Lindman H, et al. Anticancer Res. 1994 Mar-Apr;14(2A):363-6. Anticancer Res. 1994. PMID: 7912491

5

Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53.

Norberg T, Jansson T, Sjøgren S, Mårtensson C, Andréasson I, Fjällskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J. Norberg T, et al. Among authors: lindman h. Acta Oncol. 1996;35 Suppl 5:96-102. doi: 10.3109/02841869609083980. Acta Oncol. 1996. PMID: 9142977 Review.

6

Radiotherapy of breast cancer after breast-conserving surgery: an improved technique using mixed electron-photon beams with a multileaf collimator.

Jansson T, Lindman H, Nygård K, Dahlgren CV, Montelius A, Oberg-Kreuger C, Asplund S, Bergh J. Jansson T, et al. Among authors: lindman h. Radiother Oncol. 1998 Jan;46(1):83-9. doi: 10.1016/s0167-8140(97)00176-x. Radiother Oncol. 1998. PMID: 9488131 Clinical Trial.

7

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer.

Ljungman P, Björkstrand B, Fornander T, Höglund M, Juliusson G, Lindman H, Malmström A, Rotstein S, Söderberg M, Wilking N, Villman K, Bergh J. Ljungman P, et al. Among authors: lindman h. Bone Marrow Transplant. 1998 Sep;22(5):445-8. doi: 10.1038/sj.bmt.1701367. Bone Marrow Transplant. 1998. PMID: 9733267

8

FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group.

Lindman H, Wiklund T, Holte H, Ljungman P, Blomqvist C, Kvalheim G, Bengtsson M, Höglund M, Wilking N, Bergh J. Lindman H, et al. Acta Oncol. 1999;38(2):239-45. doi: 10.1080/028418699431672. Acta Oncol. 1999. PMID: 10227447 Clinical Trial.

9

Can axillary dissection be avoided by improved molecular biological diagnosis?

Lindahl T, Engel G, Ahlgren J, Klaar S, Bjöhle J, Lindman H, Andersson J, von Schoultz E, Bergh J. Lindahl T, et al. Among authors: lindman h. Acta Oncol. 2000;39(3):319-26. doi: 10.1080/028418600750013087. Acta Oncol. 2000. PMID: 10987228 Review.

10

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N. Bergh J, et al. Among authors: lindman h. Lancet. 2000 Oct 21;356(9239):1384-91. doi: 10.1016/s0140-6736(00)02841-5. Lancet. 2000. PMID: 11052580 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page